Report of Foreign Issuer (6-k)
September 09 2019 - 7:58AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
September 9, 2019
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X]
|
Form 40-F [ ]
|
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Novo Nordisk A/S – Share
repurchase programme
Bagsværd, Denmark, 9 September 2019
– On 9 August 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No
596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of
8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK
15 billion to be executed during a 12-month period beginning 1 February 2019.
Under the programme initiated 9 August 2019,
Novo Nordisk will repurchase B shares for an amount up to DKK 2.6 billion in the period from 9 August 2019 to 30 October 2019.
Since the announcement as
of 2 September 2019, the following transactions have been made:
|
Number of
B shares
|
Average
purchase price
|
Transaction
value, DKK
|
Accumulated, last announcement
|
2,054,000
|
|
712,638,600
|
2 September 2019
|
125,000
|
356.79
|
44,598,316
|
3 September 2019
|
125,000
|
360.29
|
45,036,143
|
4 September 2019
|
120,000
|
363.12
|
43,574,297
|
5 September 2019
|
130,000
|
359.40
|
46,722,098
|
6 September 2019
|
120,000
|
356.60
|
42,792,518
|
|
|
|
|
Accumulated under the programme
|
2,674,000
|
|
935,361,972
|
The details for each transaction made under the
share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total
of 33,234,044 B shares of DKK 0.20, corresponding to 1.4% of the share capital, as treasury shares. The total amount of A and
B shares in the company is 2,400,000,000 including treasury shares.
Page 2 of 2
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning
1 February 2019. As of 6 September 2019, Novo Nordisk has since 1 February 2019 repurchased a total of 26,075,012 B shares at an
average share price of DKK 328.68 per B share equal to a transaction value of DKK 8,570,315,427.
Novo Nordisk is a global healthcare
company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities
that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered
in Denmark, Novo Nordisk employs approximately 41,600 people in 80 countries and markets its products in more than 170 countries.
Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For
more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
Further information
Media:
|
|
|
Anne Margrethe Hauge
|
+45 4442 3450
|
amhg@novonordisk.com
|
Ken Inchausti (US)
|
+1 609 240 9429
|
kiau@novonordisk.com
|
|
|
|
Investors:
|
|
|
Peter Hugreffe Ankersen
|
+45 3075 9085
|
phak@novonordisk.com
|
Valdemar Borum Svarrer
|
+45 3079 0301
|
jvls@novonordisk.com
|
Ann Søndermølle Rendbæk
|
+45 3075 2253
|
arnd@novonordisk.com
|
Kristoffer Due Berg (US)
|
+1 609 235 2989
|
krdb@novonordisk.com
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
|
|
|
Company announcement No 52 / 2019
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: September 9, 2019
|
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer
|
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Apr 2024 to May 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From May 2023 to May 2024